Cargando…

A novel approach to cardiovascular disturbances in patients with schizophrenia spectrum disorders treated with long-acting injectable medication

PURPOSE: This research article assesses the cardiovascular impact of long-term injectable antipsychotic therapy on patients diagnosed with schizophrenia spectrum disorders. In our study, we attempted to quantify the potential causes of cardiovascular damage, assess cardiovascular parameters, and cor...

Descripción completa

Detalles Bibliográficos
Autores principales: Andor, Minodora, Dehelean, Liana, Romosan, Ana-Maria, Buda, Valentina, Radu, Gabriela, Caruntu, Florina, Bordejevic, Aurora, Manea, Minodora Marinela, Papava, Ion, Bredicean, Cristina Ana, Romosan, Radu Stefan, Tomescu, Mirela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354682/
https://www.ncbi.nlm.nih.gov/pubmed/30774346
http://dx.doi.org/10.2147/NDT.S186892
_version_ 1783391217161076736
author Andor, Minodora
Dehelean, Liana
Romosan, Ana-Maria
Buda, Valentina
Radu, Gabriela
Caruntu, Florina
Bordejevic, Aurora
Manea, Minodora Marinela
Papava, Ion
Bredicean, Cristina Ana
Romosan, Radu Stefan
Tomescu, Mirela
author_facet Andor, Minodora
Dehelean, Liana
Romosan, Ana-Maria
Buda, Valentina
Radu, Gabriela
Caruntu, Florina
Bordejevic, Aurora
Manea, Minodora Marinela
Papava, Ion
Bredicean, Cristina Ana
Romosan, Radu Stefan
Tomescu, Mirela
author_sort Andor, Minodora
collection PubMed
description PURPOSE: This research article assesses the cardiovascular impact of long-term injectable antipsychotic therapy on patients diagnosed with schizophrenia spectrum disorders. In our study, we attempted to quantify the potential causes of cardiovascular damage, assess cardiovascular parameters, and correlate them with the time elapsed from the onset of the psychosis until the initiation of injectable antipsychotic therapy, as well as the duration of long-acting therapy, and finally, to compare two of the most utilized long-acting injectable (LAI) medications (olanzapine vs risperidone). PATIENTS AND METHODS: This cross-sectional study recruited 64 patients of 2 outpatient clinics undergoing treatment with LAI antipsychotics for schizophrenic spectrum disorder. The study reports outpatients’ clinical data, laboratory blood sample findings, routine echocardiography, as well as speckle tracking echocardiography. RESULTS: Among patients with longer durations of pre-long-acting antipsychotic treatment, body mass indices, mitral velocity wave values (E and A waves), and the global longitudinal strain (GLS) measurements significantly correlated with patients’ myocardial contractility. The study also found that GLS was significantly lower in the group in which pre-LAI duration was prolonged, and was not influenced by the duration of LAI treatment. Furthermore, patients receiving olanzapine showed significantly improved myocardial contractility as measured by the aforementioned parameters, in comparison with patients treated with risperidone. CONCLUSION: The results of our study indicate that patients suffering from schizophrenia and who are left untreated or poorly treated for a longer period of time may develop myocardial impairment. The changes may be both secondary to a high prevalence of cardiovascular risk factors and may also be generated by the disease per se. The group who received olanzapine demonstrated improved results for a longer period of time without proper medication.
format Online
Article
Text
id pubmed-6354682
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-63546822019-02-15 A novel approach to cardiovascular disturbances in patients with schizophrenia spectrum disorders treated with long-acting injectable medication Andor, Minodora Dehelean, Liana Romosan, Ana-Maria Buda, Valentina Radu, Gabriela Caruntu, Florina Bordejevic, Aurora Manea, Minodora Marinela Papava, Ion Bredicean, Cristina Ana Romosan, Radu Stefan Tomescu, Mirela Neuropsychiatr Dis Treat Original Research PURPOSE: This research article assesses the cardiovascular impact of long-term injectable antipsychotic therapy on patients diagnosed with schizophrenia spectrum disorders. In our study, we attempted to quantify the potential causes of cardiovascular damage, assess cardiovascular parameters, and correlate them with the time elapsed from the onset of the psychosis until the initiation of injectable antipsychotic therapy, as well as the duration of long-acting therapy, and finally, to compare two of the most utilized long-acting injectable (LAI) medications (olanzapine vs risperidone). PATIENTS AND METHODS: This cross-sectional study recruited 64 patients of 2 outpatient clinics undergoing treatment with LAI antipsychotics for schizophrenic spectrum disorder. The study reports outpatients’ clinical data, laboratory blood sample findings, routine echocardiography, as well as speckle tracking echocardiography. RESULTS: Among patients with longer durations of pre-long-acting antipsychotic treatment, body mass indices, mitral velocity wave values (E and A waves), and the global longitudinal strain (GLS) measurements significantly correlated with patients’ myocardial contractility. The study also found that GLS was significantly lower in the group in which pre-LAI duration was prolonged, and was not influenced by the duration of LAI treatment. Furthermore, patients receiving olanzapine showed significantly improved myocardial contractility as measured by the aforementioned parameters, in comparison with patients treated with risperidone. CONCLUSION: The results of our study indicate that patients suffering from schizophrenia and who are left untreated or poorly treated for a longer period of time may develop myocardial impairment. The changes may be both secondary to a high prevalence of cardiovascular risk factors and may also be generated by the disease per se. The group who received olanzapine demonstrated improved results for a longer period of time without proper medication. Dove Medical Press 2019-01-25 /pmc/articles/PMC6354682/ /pubmed/30774346 http://dx.doi.org/10.2147/NDT.S186892 Text en © 2019 Andor et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Andor, Minodora
Dehelean, Liana
Romosan, Ana-Maria
Buda, Valentina
Radu, Gabriela
Caruntu, Florina
Bordejevic, Aurora
Manea, Minodora Marinela
Papava, Ion
Bredicean, Cristina Ana
Romosan, Radu Stefan
Tomescu, Mirela
A novel approach to cardiovascular disturbances in patients with schizophrenia spectrum disorders treated with long-acting injectable medication
title A novel approach to cardiovascular disturbances in patients with schizophrenia spectrum disorders treated with long-acting injectable medication
title_full A novel approach to cardiovascular disturbances in patients with schizophrenia spectrum disorders treated with long-acting injectable medication
title_fullStr A novel approach to cardiovascular disturbances in patients with schizophrenia spectrum disorders treated with long-acting injectable medication
title_full_unstemmed A novel approach to cardiovascular disturbances in patients with schizophrenia spectrum disorders treated with long-acting injectable medication
title_short A novel approach to cardiovascular disturbances in patients with schizophrenia spectrum disorders treated with long-acting injectable medication
title_sort novel approach to cardiovascular disturbances in patients with schizophrenia spectrum disorders treated with long-acting injectable medication
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354682/
https://www.ncbi.nlm.nih.gov/pubmed/30774346
http://dx.doi.org/10.2147/NDT.S186892
work_keys_str_mv AT andorminodora anovelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication
AT deheleanliana anovelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication
AT romosananamaria anovelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication
AT budavalentina anovelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication
AT radugabriela anovelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication
AT caruntuflorina anovelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication
AT bordejevicaurora anovelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication
AT maneaminodoramarinela anovelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication
AT papavaion anovelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication
AT brediceancristinaana anovelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication
AT romosanradustefan anovelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication
AT tomescumirela anovelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication
AT andorminodora novelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication
AT deheleanliana novelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication
AT romosananamaria novelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication
AT budavalentina novelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication
AT radugabriela novelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication
AT caruntuflorina novelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication
AT bordejevicaurora novelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication
AT maneaminodoramarinela novelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication
AT papavaion novelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication
AT brediceancristinaana novelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication
AT romosanradustefan novelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication
AT tomescumirela novelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication